Posts Tagged ‘multimodal therapy’

Disrupting autophagy found to improve chemosensitivity

15 Nov 2017 by under Research/Treatment

598px Chemotherapy vials 3 100x100 Disrupting autophagy found to improve chemosensitivityMesothelioma treatment often involves using drug pemetrexed, but as many as 60 percent of patients see no improvement. Researchers may have found a way to improve the effects of chemo though, according to Surviving Mesothelioma. (more…)


Study: Older pleural mesothelioma patients less likely to receive treatment

30 Aug 2017 by under Research/Treatment

220px Effusionhalf1 100x100 Study: Older pleural mesothelioma patients less likely to receive treatment has established a reputation for its long latency period. It can take 30-plus years to develop the cancer after initial exposure to , meaning a young person exposed to likely wouldn’t receive a mesothelioma diagnosis until he is a senior citizen. A recent study determined that the older a person with mesothelioma is, the less likely they are to receive treatment for the deadly cancer. (more…)


Compound found in broccoli could help fight mesothelioma

5 Jul 2017 by under Research/Treatment

Broccoli666 100x100 Compound found in broccoli could help fight mesotheliomaEveryone says to eat your veggies to stay healthy. However, they probably didn’t realize those veggies could contain mesothelioma cancer-fighting benefits.

A recent study found the compound sulforaphane, produced in cruciferous vegetables like broccoli, Brussel sprouts, cauliflower and cabbage, could boost the number of mesothelioma cells killed with chemotherapy and cause minimal side effects, according to Surviving Mesothelioma. The researchers studied the benefits of the compound in conjunction with using cisplatin, popularly used as part of multimodal treatment for the deadly cancer that can affect the lining of the heart, lungs or abdomen and take decades to become known. (more…)


Photodynamic therapy using infrared could improve mesothelioma patient outcomes

11 Jan 2017 by under Research/Treatment

research test tubes 100x100 Photodynamic therapy using infrared could improve mesothelioma patient outcomes Research supports , using various treatment tactics, when treating mesothelioma. The deadly cancer, associated with exposure to asbestos fibers, can affect the lining of the lungs, heart or abdomen, and due to a long latency period, mesothelioma is often hard to detect until it has progressed to its later stages, making treatment difficult. Multimodal therapy often includes combinations of surgery, radiation and chemotherapy, but it can also include a possibly unexpected tool: light. (more…)


Study supports extrapleural pneumonectomy to treat select mesothelioma patients

24 Aug 2009 by under News, Research/Treatment

The results of a study published recently in The Journal of Thoracic and Cardiovascular Surgery supports the use of extrapleural pneumonectomy-based multimodal therapy in carefully selected patients with malignant pleural mesothelioma. The Journal is published by The American Association for Thoracic Surgery.

According to the research summary, the objective of the study was to evaluate the perioperative and long-term outcomes associated with extrapleural pneumonectomy for patients with malignant pleural mesothelioma. Pleural mesothelioma affects the lining of the chest cavity and lungs. Other forms of mesothelioma include pericardial, which affects the lining of the heart and is extremely rare; and peritoneal, which affects the lining of the abdomen. Mesothelioma is atributed almost exclusively to asbestos exposure.

According to the Multimedia Manual of Cardiothoracic Surgery, extrapleural pneumonectomy was introduced in the 1940s for the treatment of extensive infections of the lung and pleural space. Over the past 20 years, the extrapleural pneumonectomy technique has been modified and applied to the treatment of locally advanced malignant pleural mesothelioma, achieving substantial reductions in mortality. The surgery involves the removal of the lung with visceral and parietal pleurae, pericardium and diaphragm.

Researchers selected 70 patients between October 1994 and April 2008 to undergo the procedure. Prognostic factors included age, gender, side of disease, asbestos exposure, histology, positron emission tomography, date of surgery, neoadjuvant , completeness of cytoreduction, lymph node involvement, peioperative morbidity, adjuvant radiotherapy and pemetrexed-based .

The mean age of patients was 55 years. The median survival was 20 months, with a 3-year survival of 30 percent. Analyses showed improved survival for patients with asbestos exposure, negative lymph node involvement, and receipt of adjuvant radiation or postoperative pemetrexed-based chemotherapy.

The study was conducted by physicians from the University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital; The Baird Institute for Applied Heart and Lung Surgical; Department of Medical Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital; and Department of Radiation Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital; all in Sydney, .